Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Targeted intensification by a new preparative regimen for patients with low-grade B-cell lymphoma utilizing standard-dose yttrium-90 ibritumomab tiuxetan [ibritumomab tiuxetan Y-90] (Zevalin) radioimmunotherapy (RIT) combined with high-dose BEAM [carmustine + etoposide + cytarabine + melphalan] followed by autologous stem cell transplantation (ASCT).

Next Previous
Trial Profile

Targeted intensification by a new preparative regimen for patients with low-grade B-cell lymphoma utilizing standard-dose yttrium-90 ibritumomab tiuxetan [ibritumomab tiuxetan Y-90] (Zevalin) radioimmunotherapy (RIT) combined with high-dose BEAM [carmustine + etoposide + cytarabine + melphalan] followed by autologous stem cell transplantation (ASCT).

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 31 Mar 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cytarabine (Primary) ; Etoposide (Primary) ; Ibritumomab tiuxetan (Primary) ; Melphalan (Primary) ; Rituximab (Primary) ; Autologous stem cell therapy; Carmustine
  • Indications Follicular lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma
  • Focus Therapeutic Use
  • Acronyms Z-BEAM

    • Most Recent Events

    • 26 Mar 2022 This trial has been completed in Belgium, according to European Clinical Trials Database record. (1 Mar 2009)
    • 18 Jun 2012 Updated two-year overall survival data presented at the 17th Congress of the European Haematology Association, according to a Spectrum Pharmaceuticals media release.
    • 07 Sep 2006 Additional lead trial center and investigator identified as reported by ClinicalTrials.gov.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top